{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:14:50Z","timestamp":1788556490271,"version":"build-2803163510"},"reference-count":177,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.annonc.2021.03.199","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T02:14:01Z","timestamp":1616552041000},"page":"866-880","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Immunotherapy use outside clinical trial populations: never say never?"],"prefix":"10.1016","volume":"32","author":[{"given":"K.","family":"Rzeniewicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Turajlic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.annonc.2021.03.199_bib1","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.annonc.2021.03.199_bib2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s40264-018-0774-8","article-title":"Safety and tolerability of immune checkpoint inhibitors (PD-1 and PD-L1) in Cancer","volume":"42","author":"Baraibar","year":"2019","journal-title":"Drug Saf"},{"issue":"1","key":"10.1016\/j.annonc.2021.03.199_bib3","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2021.03.199_bib4","doi-asserted-by":"crossref","first-page":"1824645","DOI":"10.1080\/2162402X.2020.1824645","volume":"9","author":"Drakaki","year":"2020","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.annonc.2021.03.199_bib5","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2021.03.199_bib6","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1200\/JCO.19.01674","article-title":"Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease","volume":"38","author":"Abu-Sbeih","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.03.199_bib7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","article-title":"Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease","volume":"91","author":"Danlos","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2021.03.199_bib8","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2016.12.038","article-title":"Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity","volume":"75","author":"Gutzmer","year":"2017","journal-title":"Eur J Cancer"},{"issue":"19","key":"10.1016\/j.annonc.2021.03.199_bib9","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2021.03.199_bib10","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.40397","article-title":"Brief report: cancer immunotherapy in patients with preexisting rheumatic disease: the Mayo Clinic experience","volume":"70","author":"Richter","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.annonc.2021.03.199_bib11","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.annonc.2021.03.199_bib12","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejca.2020.07.023","article-title":"Safety and efficacy of atezolizumab in patients with autoimmune disease: subgroup analysis of the SAUL study in locally advanced\/metastatic urinary tract carcinoma","volume":"138","author":"Loriot","year":"2020","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2021.03.199_bib13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.annonc.2021.03.199_bib14","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2021.03.199_bib15","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/annonc\/mdw056","article-title":"The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma","volume":"27","author":"Lee","year":"2016","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2021.03.199_bib16","first-page":"169","article-title":"Severe exacerbation of myasthenia gravis associated with checkpoint inhibitor immunotherapy","volume":"4","author":"Cooper","year":"2017","journal-title":"J\u00a0Neuromuscul Dis"},{"issue":"1","key":"10.1016\/j.annonc.2021.03.199_bib17","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.25141","article-title":"Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab","volume":"54","author":"Lau","year":"2016","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.annonc.2021.03.199_bib18","first-page":"119","article-title":"Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis","volume":"78","author":"Maeda","year":"2016","journal-title":"Nagoya J Med Sci"},{"issue":"1","key":"10.1016\/j.annonc.2021.03.199_bib19","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s40425-019-0626-9","article-title":"Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?","volume":"7","author":"Zaremba","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"4","key":"10.1016\/j.annonc.2021.03.199_bib20","article-title":"Pembrolizumab therapy triggering an exacerbation of preexisting autoimmune disease: a report of 2 patient cases","volume":"4","author":"Phadke","year":"2016","journal-title":"J\u00a0Investig Med High Impact Case Rep"},{"issue":"2","key":"10.1016\/j.annonc.2021.03.199_bib21","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/ana.24715","article-title":"CTLA4 as immunological checkpoint in the development of multiple sclerosis","volume":"80","author":"Gerdes","year":"2016","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.annonc.2021.03.199_bib22","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1177\/1352458514549403","article-title":"Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma","volume":"21","author":"Gettings","year":"2015","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/j.annonc.2021.03.199_bib23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40425-014-0035-z","article-title":"Ipilimumab in patients with melanoma and autoimmune disease","volume":"2","author":"Kyi","year":"2014","journal-title":"J\u00a0Immunother Cancer"},{"issue":"6","key":"10.1016\/j.annonc.2021.03.199_bib24","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.annonc.2020.03.285","article-title":"Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy","volume":"31","author":"Haanen","year":"2020","journal-title":"Ann Oncol"},{"issue":"2569","key":"10.1016\/j.annonc.2021.03.199_bib25","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.3389\/fimmu.2018.02569","article-title":"T-cell exhaustion in chronic infections: reversing the state of exhaustion and reinvigorating optimal protective immune responses","volume":"9","author":"Saeidi","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.annonc.2021.03.199_bib26","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ijid.2017.01.028","article-title":"Anti-PD-1\/PD-L1 therapy for infectious diseases: learning from the cancer paradigm","volume":"56","author":"Rao","year":"2017","journal-title":"Int J Infect Dis"},{"issue":"7","key":"10.1016\/j.annonc.2021.03.199_bib27","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/jamaoncol.2020.0465","article-title":"Assessment of the feasibility and safety of durvalumab for treatment of solid tumors in patients with HIV-1 Infection: the phase 2 DURVAST study","volume":"6","author":"Gonzalez-Cao","year":"2020","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2021.03.199_bib28","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jamaoncol.2019.2244","article-title":"Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer\u2014a phase 1 study","volume":"5","author":"Uldrick","year":"2019","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2021.03.199_bib29","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/s40425-019-0771-1","article-title":"Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection","volume":"7","author":"Shah","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annonc.2021.03.199_bib30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejca.2018.09.017","article-title":"Anti-PD-1\/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B\/C infection","volume":"104","author":"Tio","year":"2018","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.annonc.2021.03.199_bib31","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2326-6066.CIR-18-0121","article-title":"Successful treatment of HIV-associated Kaposi sarcoma with immune checkpoint blockade","volume":"6","author":"Galanina","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"10.1016\/j.annonc.2021.03.199_bib32","first-page":"379","article-title":"Nivolumab treatment for cancers in the HIV-infected population","volume":"41","author":"Chang","year":"2018","journal-title":"J\u00a0Immunother"},{"issue":"12","key":"10.1016\/j.annonc.2021.03.199_bib33","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1093\/annonc\/mdx538","article-title":"Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients","volume":"28","author":"Heppt","year":"2017","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2021.03.199_bib34","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jtho.2018.03.031","article-title":"Safety and efficacy of PD-1 inhibitors among HIV-positive patients with non-small cell lung cancer","volume":"13","author":"Ostios-Garcia","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.annonc.2021.03.199_bib35","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2018.36.5_suppl.136","article-title":"Safety and efficacy of checkpoint inhibition (CI) in cancer patients (pts) with concurrent human immunodeficiency virus (HIV) infection","volume":"36","author":"Park","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.03.199_bib36","first-page":"2989048","article-title":"Outcomes of programmed cell death protein 1 (PD-1) and programmed death-ligand 1(PD-L1) inhibitor therapy in HIV patients with advanced cancer","volume":"2019","author":"Bari","year":"2019","journal-title":"J\u00a0Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2021.03.199_bib37","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/QAD.0000000000000562","article-title":"Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma","volume":"29","author":"Wightman","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.annonc.2021.03.199_bib38","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1097\/QAD.0000000000001849","article-title":"Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency","volume":"32","author":"Evans","year":"2018","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.annonc.2021.03.199_bib39","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/annonc\/mdx696","article-title":"Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer","volume":"29","author":"Guihot","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2021.03.199_bib40","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1097\/QAD.0000000000001429","article-title":"Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab","volume":"31","author":"Le Garff","year":"2017","journal-title":"AIDS"},{"issue":"10","key":"10.1016\/j.annonc.2021.03.199_bib41","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1093\/annonc\/mdy259","article-title":"Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection","volume":"29","author":"Scully","year":"2018","journal-title":"Ann Oncol"},{"issue":"10088","key":"10.1016\/j.annonc.2021.03.199_bib42","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.annonc.2021.03.199_bib43","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A\u00a0clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"11","key":"10.1016\/j.annonc.2021.03.199_bib44","doi-asserted-by":"crossref","first-page":"e3518","DOI":"10.1016\/S1569-9056(19)34669-X","article-title":"Nivolumab in metastatic renal cell carcinoma (mRCC) patients with chronic hepatitis C virus (HCV) infection","volume":"18","author":"Tsimafeyeu","year":"2019","journal-title":"Eur Urol Suppl"},{"issue":"1","key":"10.1016\/j.annonc.2021.03.199_bib45","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s40425-019-0808-5","article-title":"Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition","volume":"7","author":"Zhang","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"7","key":"10.1016\/j.annonc.2021.03.199_bib46","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1002\/cam4.2868","article-title":"PD-1 inhibitors for non-small cell lung cancer patients with special issues: real-world evidence","volume":"9","author":"Byeon","year":"2020","journal-title":"Cancer Med"},{"issue":"7","key":"10.1016\/j.annonc.2021.03.199_bib47","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1200\/JOP.2016.019224","article-title":"Antitumor and anti-hepatitis C viral response after administration of the anti-programmed death 1 antibody pembrolizumab","volume":"13","author":"Jang","year":"2017","journal-title":"J\u00a0Oncol Pract"},{"issue":"19","key":"10.1016\/j.annonc.2021.03.199_bib48","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.1200\/JCO.2012.46.5831","article-title":"Ipilimumab-induced hepatitis C viral suppression","volume":"31","author":"Minter","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.03.199_bib49","first-page":"1","article-title":"Nivolumab and anti-HCV activity, a case report","author":"Wuyts","year":"2020","journal-title":"Acta Clin Belg"},{"issue":"1","key":"10.1016\/j.annonc.2021.03.199_bib50","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40425-014-0033-1","article-title":"Ipilimumab administration for advanced melanoma in patients with pre-existing hepatitis B or C infection: a multicenter, retrospective case series","volume":"2","author":"Ravi","year":"2014","journal-title":"J\u00a0Immunother Cancer"},{"issue":"5","key":"10.1016\/j.annonc.2021.03.199_bib51","doi-asserted-by":"crossref","first-page":"e19013","DOI":"10.1097\/MD.0000000000019013","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with HBV\/HCV infection and advanced-stage cancer: a systematic review","volume":"99","author":"Pu","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.annonc.2021.03.199_bib52","doi-asserted-by":"crossref","first-page":"e001145","DOI":"10.1136\/jitc-2020-001145","article-title":"On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19","volume":"8","author":"Gambichler","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2021.03.199_bib53","doi-asserted-by":"crossref","first-page":"e000897","DOI":"10.1136\/jitc-2020-000897","article-title":"Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients","volume":"8","author":"Leiter","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2021.03.199_bib54","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S2352-3026(18)30217-5","article-title":"Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1\/2a study","volume":"6","author":"Younes","year":"2019","journal-title":"Lancet Haematol"},{"issue":"26","key":"10.1016\/j.annonc.2021.03.199_bib55","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.annonc.2021.03.199_bib56","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s12032-019-1316-7","article-title":"Liver graft rejection following immune checkpoint inhibitors treatment: a review","volume":"36","author":"Hu","year":"2019","journal-title":"Med Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2021.03.199_bib57","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1111\/ajt.15811","article-title":"Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: a systematic review","volume":"20","author":"d'Izarny-Gargas","year":"2020","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.annonc.2021.03.199_bib58","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1634\/theoncologist.2019-0659","article-title":"The safety and efficacy of checkpoint inhibitors in transplant recipients: a case series and systematic review of literature","volume":"25","author":"Kumar","year":"2020","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.annonc.2021.03.199_bib59","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s40425-019-0585-1","article-title":"Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature","volume":"7","author":"Abdel-Wahab","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"9","key":"10.1016\/j.annonc.2021.03.199_bib60","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s00262-020-02644-2","article-title":"Impact of corticosteroids on allograft protection in renal transplant patients receiving anti-PD-1 immunotherapy","volume":"69","author":"Danesh","year":"2020","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"10.1016\/j.annonc.2021.03.199_bib61","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ekir.2019.11.015","article-title":"Systematic review of the safety of immune checkpoint inhibitors among kidney transplant patients","volume":"5","author":"Manohar","year":"2019","journal-title":"Kidney Inter Rep"},{"issue":"21","key":"10.1016\/j.annonc.2021.03.199_bib62","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1002\/cncr.33134","article-title":"Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: a single-center analysis","volume":"126","author":"Owoyemi","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2021.03.199_bib63","doi-asserted-by":"crossref","first-page":"e000908","DOI":"10.1136\/jitc-2020-000908","article-title":"Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients","volume":"8","author":"Trager","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2021.03.199_bib64","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/onco.13539","article-title":"A\u00a0pilot study of checkpoint inhibitors in solid organ transplant recipients with metastatic cutaneous squamous cell carcinoma","volume":"26","author":"Tsung","year":"2021","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.annonc.2021.03.199_bib65","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/TP.0000000000002914","article-title":"Poor outcomes with the use of checkpoint inhibitors in kidney transplant recipients","volume":"104","author":"Venkatachalam","year":"2020","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.annonc.2021.03.199_bib66","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.hbpd.2019.09.011","article-title":"Immune checkpoint inhibitor for hepatocellular carcinoma recurrence after liver transplantation","volume":"19","author":"Zhuang","year":"2020","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"3","key":"10.1016\/j.annonc.2021.03.199_bib67","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/ajt.15617","article-title":"Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: are checkpoint inhibitors safe for the pretransplant patient?","volume":"20","author":"Nordness","year":"2020","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.annonc.2021.03.199_bib68","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1056\/NEJMc1614298","article-title":"Preserved renal-allograft function and the PD-1 pathway inhibitor nivolumab","volume":"376","author":"Barnett","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.annonc.2021.03.199_bib69","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1038\/s41467-019-12628-1","article-title":"Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation","volume":"10","author":"Esfahani","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.annonc.2021.03.199_bib70","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbmt.2018.08.028","article-title":"Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation","volume":"25","author":"Ijaz","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.annonc.2021.03.199_bib71","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1634\/theoncologist.2017-0004","article-title":"FDA approval summary: nivolumab for the treatment of relapsed or progressive classical hodgkin lymphoma","volume":"22","author":"Kasamon","year":"2017","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.annonc.2021.03.199_bib72","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1038\/s41375-020-0851-8","article-title":"Posttransplant cyclophosphamide after allogeneic hematopoietic cell transplantation mitigates the immune activation induced by previous nivolumab therapy","volume":"34","author":"Nieto","year":"2020","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.annonc.2021.03.199_bib73","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s12185-020-02960-4","article-title":"Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study","volume":"112","author":"Ito","year":"2020","journal-title":"Int J Hematol"},{"issue":"4","key":"10.1016\/j.annonc.2021.03.199_bib74","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/bmt.2012.187","article-title":"Risk and prognostic factors for acute GVHD based on NIH consensus criteria","volume":"48","author":"Lee","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.annonc.2021.03.199_bib75","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/sj.bmt.1703111","article-title":"Chronic graft-versus-host disease: clinical manifestation and therapy","volume":"28","author":"Ratanatharathorn","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"24","key":"10.1016\/j.annonc.2021.03.199_bib76","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1182\/blood.2019004710","article-title":"A\u00a0multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation","volume":"135","author":"Davids","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.annonc.2021.03.199_bib77","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2018-02-811174","article-title":"Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil","volume":"132","author":"Herbaux","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.annonc.2021.03.199_bib78","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/cncr.30642","article-title":"Immune checkpoint inhibitors in challenging populations","volume":"123","author":"Johnson","year":"2017","journal-title":"Cancer"},{"issue":"10031","key":"10.1016\/j.annonc.2021.03.199_bib79","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"issue":"10064","key":"10.1016\/j.annonc.2021.03.199_bib80","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2021.03.199_bib81","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s40425-016-0166-5","article-title":"Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction","volume":"4","author":"Kanz","year":"2016","journal-title":"J\u00a0immunother Cancer"},{"issue":"11","key":"10.1016\/j.annonc.2021.03.199_bib82","doi-asserted-by":"crossref","first-page":"e1753","DOI":"10.1634\/theoncologist.2020-0055","article-title":"Organ dysfunction in patients with advanced melanoma treated with immune checkpoint inhibitors","volume":"25","author":"Spillane","year":"2020","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.annonc.2021.03.199_bib83","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.jtho.2019.05.010","article-title":"Safety, efficacy, and patient-reported health-related quality of life and symptom burden with nivolumab in patients with advanced non\u2013small cell lung cancer, including patients aged 70 years or older or with poor performance status (CheckMate 153)","volume":"14","author":"Spigel","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.annonc.2021.03.199_bib84","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejca.2019.11.019","article-title":"CheckMate 171: a phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations","volume":"127","author":"Felip","year":"2020","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.annonc.2021.03.199_bib85","doi-asserted-by":"crossref","first-page":"S214","DOI":"10.1016\/j.jtho.2019.08.424","article-title":"OA04.02 CheckMate 817: first-line nivolumab\u00a0+ ipilimumab in patients with ECOG PS 2 and other special populations with advanced NSCLC","volume":"14","author":"Barlesi","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2021.03.199_bib86","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S2213-2600(20)30033-3","article-title":"Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial","volume":"8","author":"Middleton","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"11","key":"10.1016\/j.annonc.2021.03.199_bib87","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2021.03.199_bib88","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.eururo.2019.03.015","article-title":"Primary results from SAUL, a multinational single-arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial carcinoma of the urinary tract","volume":"76","author":"Sternberg","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.annonc.2021.03.199_bib89","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.lungcan.2020.04.027","article-title":"ECOG performance status \u22652 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors\u2014a systematic review and meta-analysis of real world data","volume":"145","author":"Dall'Olio","year":"2020","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.annonc.2021.03.199_bib90","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1634\/theoncologist.2020-0014","article-title":"Efficacy and safety of immune checkpoint inhibitors in patients with microsatellite instability-high end-stage cancers and poor performance status related to high disease burden","volume":"25","author":"Pietrantonio","year":"2020","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.annonc.2021.03.199_bib91","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/ajco.12702","article-title":"Clinical and palliative care outcomes for patients of poor performance status treated with antiprogrammed death-1 monoclonal antibodies for advanced melanoma","volume":"13","author":"Wong","year":"2017","journal-title":"Asia-Pac J Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2021.03.199_bib92","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/1049909119862785","article-title":"Immune checkpoint inhibitor use near the end of life is associated with poor performance status, lower hospice enrollment, and dying in the hospital","volume":"37","author":"Glisch","year":"2020","journal-title":"Am J Hosp Palliat Care"},{"issue":"7","key":"10.1016\/j.annonc.2021.03.199_bib93","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2021.03.199_bib94","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2021.03.199_bib95","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2021.03.199_bib96","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.annonc.2021.03.199_bib97","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.18.00204","article-title":"Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial","volume":"37","author":"Kluger","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.annonc.2021.03.199_bib98","doi-asserted-by":"crossref","first-page":"9501","DOI":"10.1200\/JCO.2019.37.15_suppl.9501","article-title":"Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204)","volume":"37","author":"Tawbi","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2021.03.199_bib99","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMe1807752","article-title":"Immunotherapy for melanoma metastatic to the brain","volume":"379","author":"Turajlic","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.03.199_bib100","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejca.2019.12.029","article-title":"ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients","volume":"127","author":"Pearson","year":"2020","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.annonc.2021.03.199_bib101","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(20)30023-1","article-title":"Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial","volume":"21","author":"Davis","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2021.03.199_bib102","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ejca.2017.09.032","article-title":"Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma","volume":"86","author":"Geoerger","year":"2017","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2021.03.199_bib103","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(19)30671-0","article-title":"Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1\u20132 trial","volume":"21","author":"Geoerger","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2021.03.199_bib104","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(19)30693-X","article-title":"Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1\u20132 study","volume":"21","author":"Geoerger","year":"2020","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2021.03.199_bib105","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1158\/1078-0432.CCR-15-0491","article-title":"Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors","volume":"22","author":"Merchant","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.annonc.2021.03.199_bib106","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1297\/cpe.28.59","article-title":"Immune checkpoint inhibitor therapy for pediatric cancers: a mini review of endocrine adverse events","volume":"28","author":"Ihara","year":"2019","journal-title":"Clin Pediatr Endocrinol"},{"issue":"21","key":"10.1016\/j.annonc.2021.03.199_bib107","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1200\/JCO.2017.76.4647","article-title":"New agents, emerging late effects, and the development of precision survivorship","volume":"36","author":"Chow","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2021.03.199_bib108","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40425-018-0336-8","article-title":"Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis","volume":"6","author":"Elias","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"issue":"4","key":"10.1016\/j.annonc.2021.03.199_bib109","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1053\/j.seminoncol.2018.08.007","article-title":"FDA analyses of survival in older adults with metastatic non\u2013small cell lung cancer in controlled trials of PD-1\/PD-L1 blocking antibodies","volume":"45","author":"Marur","year":"2018","journal-title":"Semin Oncol"},{"key":"10.1016\/j.annonc.2021.03.199_bib110","doi-asserted-by":"crossref","first-page":"103036","DOI":"10.1016\/j.critrevonc.2020.103036","article-title":"A\u00a0comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma","volume":"153","author":"Lolli","year":"2020","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"4","key":"10.1016\/j.annonc.2021.03.199_bib111","first-page":"e1568810","article-title":"Correlation between patients' age and cancer immunotherapy efficacy","volume":"8","author":"Wu","year":"2019","journal-title":"OncoImmunology"},{"issue":"21","key":"10.1016\/j.annonc.2021.03.199_bib112","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1158\/1078-0432.CCR-18-1116","article-title":"Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations","volume":"24","author":"Kugel","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.annonc.2021.03.199_bib113","first-page":"10010","article-title":"FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancers","volume":"34","author":"Harpreet","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.annonc.2021.03.199_bib114","doi-asserted-by":"crossref","first-page":"10009","DOI":"10.1200\/JCO.2016.34.15_suppl.10009","article-title":"Efficacy and safety of checkpoint blockade for treatment of advanced melanoma (mel) in patients (pts) age 80 and older (80+)","volume":"34","author":"Friedman","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.03.199_bib115","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.lungcan.2019.08.030","article-title":"Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer","volume":"137","author":"Galli","year":"2019","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.annonc.2021.03.199_bib116","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40266-019-00697-2","article-title":"Efficacy and adverse events of immunotherapy with checkpoint inhibitors in older patients with cancer","volume":"36","author":"van Holstein","year":"2019","journal-title":"Drugs Aging"},{"issue":"5","key":"10.1016\/j.annonc.2021.03.199_bib117","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/jgs.15750","article-title":"Immune checkpoint inhibitors in real-world treatment of older adults with non\u2013small cell lung cancer","volume":"67","author":"Muchnik","year":"2019","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"15","key":"10.1016\/j.annonc.2021.03.199_bib118","doi-asserted-by":"crossref","first-page":"e15077","DOI":"10.1200\/JCO.2018.36.15_suppl.e15077","article-title":"Treating the elderly with immune checkpoint inhibitors: real life experience from a large Brazilian center","volume":"36","author":"Silva","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2021.03.199_bib119","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1016\/S1470-2045(18)30348-6","article-title":"Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer","volume":"19","author":"Soto-Perez-de-Celis","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2021.03.199_bib120","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejogrb.2017.04.023","article-title":"Maternal and perinatal outcomes in pregnancy-associated melanoma. Report of two cases and a systematic literature review","volume":"214","author":"Mendiz\u00e1bal","year":"2017","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.annonc.2021.03.199_bib121","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3389\/fimmu.2019.00846","article-title":"Immune checkpoint molecules in reproductive immunology","volume":"10","author":"Miko","year":"2019","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.annonc.2021.03.199_bib122","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/eji.201948382","article-title":"Immune checkpoint molecules in pregnancy: focus on regulatory T cells","volume":"50","author":"Zhang","year":"2020","journal-title":"Eur J Immunol"},{"issue":"3","key":"10.1016\/j.annonc.2021.03.199_bib131","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/CMR.0000000000000586","article-title":"Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature","volume":"29","author":"Xu","year":"2019","journal-title":"Melanoma Res"},{"issue":"3","key":"10.1016\/j.annonc.2021.03.199_bib132","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.seminoncol.2018.03.003","article-title":"Viable pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy","volume":"45","author":"Burotto","year":"2018","journal-title":"Semin Oncol"},{"key":"10.1016\/j.annonc.2021.03.199_bib133","first-page":"1","article-title":"Case report of a pregnancy during ipilimumab therapy","volume":"4","author":"Mehta","year":"2018","journal-title":"J\u00a0Glob Oncol"},{"key":"10.1016\/j.annonc.2021.03.199_bib134","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ejca.2018.09.008","article-title":"Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy","volume":"104","author":"Menzer","year":"2018","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.annonc.2021.03.199_bib135","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/CMR.0000000000000657","article-title":"Conception and viable twin pregnancy in a patient with metastatic melanoma while treated with CTLA-4 and PD-1 checkpoint inhibition","volume":"30","author":"Bucheit","year":"2020","journal-title":"Melanoma Res"},{"issue":"3","key":"10.1016\/j.annonc.2021.03.199_bib136","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/pcmr.12835","article-title":"Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: a retrospective single-centre experience in patients with BRAF-mutated melanoma","volume":"33","author":"Reijers","year":"2020","journal-title":"Pigment Cell Melanoma Res"},{"issue":"8","key":"10.1016\/j.annonc.2021.03.199_bib137","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1001\/jamaoncol.2020.2288","article-title":"Association of BRAF V600E\/K mutation status and prior BRAF\/MEK inhibition with pembrolizumab outcomes in advanced melanoma: pooled analysis of 3 clinical trials","volume":"6","author":"Puzanov","year":"2020","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2021.03.199_bib138","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/CMR.0000000000000493","article-title":"Toxicities with targeted therapies after immunotherapy in metastatic melanoma","volume":"28","author":"Grogan","year":"2018","journal-title":"Melanoma Res"},{"issue":"6","key":"10.1016\/j.annonc.2021.03.199_bib139","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/cncr.31889","article-title":"Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy","volume":"125","author":"Saab","year":"2019","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2021.03.199_bib140","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41416-018-0104-z","article-title":"The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma","volume":"119","author":"Barata","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annonc.2021.03.199_bib141","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ejca.2019.04.003","article-title":"Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors","volume":"114","author":"Shah","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2021.03.199_bib142","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejca.2018.11.031","article-title":"Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma","volume":"108","author":"Auvray","year":"2019","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.annonc.2021.03.199_bib143","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1001\/jamaoncol.2017.4526","article-title":"EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer","volume":"4","author":"Oshima","year":"2018","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2021.03.199_bib144","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.annonc.2020.01.013","article-title":"TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer","volume":"31","author":"Oxnard","year":"2020","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2021.03.199_bib145","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/annonc\/mdz077","article-title":"Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib","volume":"30","author":"Schoenfeld","year":"2019","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2021.03.199_bib146","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.annonc.2021.03.199_bib147","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","article-title":"Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma","volume":"24","author":"Amaria","year":"2018","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.annonc.2021.03.199_bib148","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","article-title":"Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial","volume":"20","author":"Rozeman","year":"2019","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2021.03.199_bib149","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","article-title":"A\u00a0single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma","volume":"25","author":"Huang","year":"2019","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.annonc.2021.03.199_bib150","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jtcvs.2018.11.124","article-title":"Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer","volume":"158","author":"Bott","year":"2019","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"issue":"21","key":"10.1016\/j.annonc.2021.03.199_bib151","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.annonc.2021.03.199_bib152","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/JCO.2019.37.15_suppl.8503","article-title":"Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): interim analysis and biomarker data from a multicenter study (LCMC3)","volume":"37","author":"Kwiatkowski","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.03.199_bib153","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fonc.2017.00121","article-title":"The feasibility and safety of surgery in patients receiving immune checkpoint inhibitors: a retrospective study","volume":"7","author":"Elias","year":"2017","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2021.03.199_bib154","doi-asserted-by":"crossref","first-page":"e1214788","DOI":"10.1080\/2162402X.2016.1214788","article-title":"Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma","volume":"5","author":"Liniker","year":"2016","journal-title":"Oncoimmunology"},{"issue":"16","key":"10.1016\/j.annonc.2021.03.199_bib155","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.2017.76.2229","article-title":"Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors","volume":"36","author":"Luke","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2021.03.199_bib156","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2021.03.199_bib157","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.radonc.2018.08.025","article-title":"Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: an international meta-analysis of individual patient data","volume":"130","author":"Lehrer","year":"2019","journal-title":"Radiother Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2021.03.199_bib158","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1093\/annonc\/mdx408","article-title":"Combined irradiation and targeted therapy or immune checkpoint blockade in brain metastases: toxicities and efficacy","volume":"28","author":"Tallet","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2021.03.199_bib159","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/pcmr.12775","article-title":"Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies","volume":"32","author":"Pires da Silva","year":"2019","journal-title":"Pigment Cell Melanoma Res"},{"issue":"1","key":"10.1016\/j.annonc.2021.03.199_bib160","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.annonc.2021.03.199_bib161","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2021.03.199_bib162","doi-asserted-by":"crossref","first-page":"S274","DOI":"10.1016\/j.jtho.2019.08.550","article-title":"MA07.05 Immune checkpoint inhibitor (ICPi) re-challenge: outcomes analysis in a French national cohort of non-small-cell lung cancer (NSCLC) patients","volume":"14","author":"Gobbini","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2021.03.199_bib163","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1158\/2326-6066.CIR-17-0755","article-title":"Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC","volume":"6","author":"Santini","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"10.1016\/j.annonc.2021.03.199_bib164","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2021.03.199_bib165","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/annonc\/mdx642","article-title":"Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma","volume":"29","author":"Pollack","year":"2018","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2021.03.199_bib166","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","article-title":"Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer","volume":"5","author":"Simonaggio","year":"2019","journal-title":"JAMA Oncol"},{"issue":"30","key":"10.1016\/j.annonc.2021.03.199_bib167","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1200\/JCO.19.00320","article-title":"Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis","volume":"37","author":"Abu-Sbeih","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2021.03.199_bib168","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/bjc.2016.107","article-title":"Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy","volume":"114","author":"Bowyer","year":"2016","journal-title":"B\u00a0J Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2021.03.199_bib169","doi-asserted-by":"crossref","first-page":"e000604","DOI":"10.1136\/jitc-2020-000604","article-title":"Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy","volume":"8","author":"Haanen","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"7","key":"10.1016\/j.annonc.2021.03.199_bib170","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.annonc.2020.03.290","article-title":"Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1","volume":"31","author":"Bayle","year":"2020","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2021.03.199_bib171","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/cid\/ciz202","article-title":"Safety of inactivated influenza vaccine in cancer patients receiving\u00a0immune checkpoint inhibitors","volume":"70","author":"Chong","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.annonc.2021.03.199_bib172","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40425-018-0353-7","article-title":"Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events","volume":"6","author":"L\u00e4ubli","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annonc.2021.03.199_bib173","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejca.2018.09.012","article-title":"Influenza vaccination in patients with lung cancer receiving anti\u2013programmed death receptor 1 immunotherapy does not induce immune-related adverse events","volume":"104","author":"Wijn","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2021.03.199_bib174","doi-asserted-by":"crossref","first-page":"xi17","DOI":"10.1093\/annonc\/mdx711.039","article-title":"Influenza vaccine indication during anticancer therapy with immune-checkpoint inhibitors: a transversal challenge for patient's counselling\u2014preliminary analysis of the INVIDIa study","volume":"28","author":"Bersanelli","year":"2017","journal-title":"Ann Oncol"},{"issue":"10250","key":"10.1016\/j.annonc.2021.03.199_bib175","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(20)31483-5","article-title":"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study","volume":"396","author":"Poll\u00e1n","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.annonc.2021.03.199_bib176","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","article-title":"Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19","volume":"183","author":"Sekine","year":"2020","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.annonc.2021.03.199_bib177","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","article-title":"Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity","volume":"183","author":"Rydyznski Moderbacher","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.annonc.2021.03.199_bib178","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.cell.2020.09.005","article-title":"Cancer, COVID-19, and antiviral immunity: the CAPTURE study","volume":"183","author":"Au","year":"2020","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.annonc.2021.03.199_bib179","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.immuni.2020.05.002","article-title":"Immunology of COVID-19: current state of the science","volume":"52","author":"Vabret","year":"2020","journal-title":"Immunity"},{"issue":"10241","key":"10.1016\/j.annonc.2021.03.199_bib180","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","article-title":"Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study","volume":"395","author":"Kuderer","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.annonc.2021.03.199_bib181","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/s41591-020-0979-0","article-title":"Determinants of COVID-19 disease severity in patients with cancer","volume":"26","author":"Robilotti","year":"2020","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.annonc.2021.03.199_bib182","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1158\/2159-8290.CD-20-0596","article-title":"Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers","volume":"10","author":"Luo","year":"2020","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.annonc.2021.03.199_bib183","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S1470-2045(20)30314-4","article-title":"COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study","volume":"21","author":"Garassino","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10241","key":"10.1016\/j.annonc.2021.03.199_bib184","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(20)31173-9","article-title":"COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study","volume":"395","author":"Lee","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2021.03.199_bib185","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.COVID-19-S02-01","article-title":"Abstract S02-01: Clinical characteristics and outcomes of coronavirus 2019 disease (COVID-19) in cancer patients treated with immune checkpoint inhibitors (ICI)","volume":"26","author":"Rogiers","year":"2020","journal-title":"Clin Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421010784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421010784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:03:13Z","timestamp":1760335393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753421010784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":177,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0923753421010784"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2021.03.199","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy use outside clinical trial populations: never say never?","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2021.03.199","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}